Temple Therapeutics BV Announces Publication of Key Mechanism Data for Evitar™

Below, we are re-publishing with permission the press-release issued by Temple Therapeutics BV on the 10th of September 2018

Supports Evitar’s™ Novel Approach for Preventing Acute Tissue Fibrosis (Surgical Adhesions)

Geleen, The Netherlands Temple Therapeutics BV (the “Company” or “Temple”)- September 10, 2018 – Temple, a clinical stage biopharmaceutical company focused in developing therapeutics for fibrosis and oncology, announces the publication of groundbreaking mechanistic data for Evitar™ in Reproductive Sciences, a peer reviewed journal of the Society of Reproductive Investigations. The publication includes data to support a credible hypothesis for Evitar™’s mechanism of action advanced by Temple’s CSO, Dr. Lynne Robertson. This hypothesis proposes that novel drug candidate Evitar™ modulates key upstream inflammatory mediators, such Hypoxia Inducible Factor 1 Alpha (HIF1-α) and Type 1 Collagen, which, when left unchecked, promote abnormal healing and tissue fibrosis.

Robertson, L., King, N., Diamond, M., & Saed, G., Evitar™(l-Alanyl-l-Glutamine) Regulates Key Signaling Molecules in the Pathogenesis of Postoperative Tissue Fibrosis, Reproductive Sciences, September 5, 2018

Additionally, data from the Evitar™ proof-of-concept randomized clinical trial was recently accepted for presentation at 47th Annual Global Congress of AAGL (American Association of Gynecologic Laparoscopists) scheduled for November 2018.

“Post-surgical adhesions are broadly recognized as the single greatest cause of surgical complications. Moreover, they have evaded effective intervention, until now” comments Sanj Singh, CEO of Temple. “These mechanism-of-action and randomized clinical trial data speak to the underlying biology driving surgical adhesions. We are pleased to note the publication’s acceptance in Reproductive Sciences, a high-impact, peer-reviewed journal. This publication and the forthcoming AAGL presentation further support the Evitar™ value proposition. Adhesion prevention is only the beginning. However, it provides a relevant model to further the study of both fibrosis and cancer pathophysiology. Temple is leveraging these insights to further its pipeline of first-in-class therapeutics for the management of adhesions, endometriosis and ovarian cancer.”

About Temple Therapeutics BV

Temple Therapeutics BV is a privately held Dutch based clinical stage development therapeutic drug company, developing first in class and best in class therapeutics to treat acute/chronic fibrosis and cancer. With novel targets linked by a common underlying biology, Temple’s platform has yielded three promising drug candidates to treat post-operative adhesions, endometriosis and ovarian cancer.

About Reproductive Sciences

Reproductive Sciences (RS) is a peer-reviewed, monthly journal publishing original research and reviews in obstetrics and gynecology making it one of the highest ranked and cited journals. RS is multi-disciplinary and includes research in basic reproductive biology and medicine, maternal-fetal medicine, obstetrics, gynecology, reproductive endocrinology, urogynecology, fertility/infertility, embryology, gynecologic/reproductive oncology, developmental biology, stem cell research, molecular/cellular biology and other related fields.

* The study was conducted by Clinical Accelerator

This entry was posted in Biotech, Clinical Accelerator. Bookmark the permalink.

Leave a Reply

Please log in using one of these methods to post your comment:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s